Scholars@Duke
Keith Michael Sullivan

Keith Michael Sullivan

James B. Wyngaarden Distinguished Professor Emeritus of Medicine
Medicine, Hematologic Malignancies and Cellular Therapy
sulli025@mc.duke.edu
Box 3961 Med Ctr, Durham, NC 27710
Cellular Therapy ABMT, Box 3961 DUMC, Durham, NC 27705

Scholarly Works - Conferences

Myeloablation Followed by Hematopoietic Stem Cell Transplantation and Long-Term Normalization of Systemic Sclerosis Molecular Signatures.

Conference Arthritis Rheumatol · August 2024 OBJECTIVE: In the randomized Scleroderma: Cyclophosphamide or Transplantation (SCOT) trial, myeloablation, followed by hematopoietic stem cell transplantation (HSCT), led to the normalization of systemic sclerosis (SSc) peripheral blood cell (PBC) gene exp ... Full text Link to item Cite

Cognitive impairment in candidates for allogeneic hematopoietic stem cell transplantation.

Conference Bone Marrow Transplant · January 2022 Hematopoietic cell transplant (HCT) is an increasingly common and curative treatment strategy to improve survival among individuals with malignant and nonmalignant diseases, with over one million HCTs having been performed worldwide. Neurocognitive dysfunc ... Full text Link to item Cite

Pre-Transplant Hepatic Steatosis (fatty liver) Predicts Chronic Graft-Vs-Host Disease but Does Not Affect Mortality

Conference Blood · November 13, 2019 Introduction: Allogeneic hematopoietic stem cell transplant (allo-HCT) remains the only curative treatment for many hematologic conditions. However, significant mortality risk and risk of severe graft-vs-host disease (GvHD) limit its usefulness. So ... Full text Cite

A Phase II Trial to Compare Allogeneic Transplant Vs. Standard of Care for Severe Sickle Cell Disease: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 1503

Conference Blood · November 13, 2019 Background: Allogeneic hematopoietic cell transplantation (HCT) is a curative treatment for sickle cell disease (SCD). A pilot trial confirmed the suitability of a myeloablative conditioning regimen (busulfan/fludarabine/r-ATG) for HLA-matched sibl ... Full text Cite

611 A novel method of objectively quantifying cutaneous sclerosis

Conference Journal of Investigative Dermatology · May 2018 Full text Cite

Predicting Mortality in Systemic Sclerosis-Related Interstitial Lung Disease in Two Independent Cohorts

Conference AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE · 2018 Link to item Cite

Adult Umbilical Cord Blood Transplantation Using Myeloablative Thiotepa, Total Body Irradiation, and Fludarabine Conditioning.

Conference Biol Blood Marrow Transplant · November 2017 Treatment-related mortality (TRM) remains elevated in adult patients undergoing umbilical cord blood transplantation (UCBT), including an early rise in TRM suggestive of excessive toxicity associated with the standard myeloablative total body irradiation ( ... Full text Link to item Cite

Adult Umbilical Cord Blood Transplantation Using Myeloablative Total Body Irradiation, Fludarabine, and Thiotepa Conditioning

Conference Blood · December 2, 2016 AbstractIntroduction: Umbilical cord blood (UCB) extends the curative potential of stem cell transplantation to adult patients without a suitable donor. The most commonly used myeloablative preparative regim ... Full text Cite

Efficacy of Autologous Stem Cell Transplantation in Older Multiple Myeloma Patients

Conference Biology of Blood and Marrow Transplantation · March 2016 Full text Cite

Results of a Multicenter Pilot Investigation of Bone Marrow Transplantation in Adults with Sickle Cell Disease (STRIDE)

Conference Blood · December 3, 2015 AbstractBackground: Hematopoietic cell transplantation (HCT) for sickle cell disease (SCD) is potentially curative, yet applied sparingly in adults due in part to limited donor avai ... Full text Cite

Novel imaging techniques for quantifying cutaneous sclerosis

Conference JOURNAL OF INVESTIGATIVE DERMATOLOGY · May 2015 Link to item Cite

Late Gastrointestinal Complications of Allogeneic Hematopoietic Stem Cell Transplantation

Conference Biology of Blood and Marrow Transplantation · February 2015 Full text Cite

PANEL SESSION REPORT: SYSTEMIC SCLEROSIS

Conference BONE MARROW TRANSPLANTATION · February 2010 Link to item Cite

Long Term Survival Following High-dose Sequential Therapy with Autologous Hematopoietic Cell Rescue for Multiple Myeloma

Conference · 2010 High-dose therapy (HDT) with autologous hematopoietic cell rescue (AHCR) improves survival in patients with multiple myeloma, but is not curative due to a continuous risk of relapse. One approach to try to reduce relapse is to optimize the pretransplant t ... Cite

TU‐EE‐A2‐05: Challenges in Limiting Kidney Dose When Delivering Total Body Irradiation (TBI) for Patients with Severe Systemic Sclerosis (SSc)

Conference Medical Physics · January 1, 2007 Purpose: To describe challenges in limiting kidney dose when delivering TBI to SSc patients enrolled on a multicenter Phase II/III SCOT (Scleroderma Cyclophosphamide or Transplantation) protocol. Material and Methods: The SCOT protocol uses a preparative r ... Full text Cite

Outcome and Immune Reconstitution Following T Cell Depleted Nonmyeloablative Allogeneic Transplantation Using Matched Donors.

Conference Blood · November 16, 2005 AbstractTo minimize toxicity and monitor immune recovery without interference of long term use of immunosuppressive agents, we have investigated T-cell depleted, nonmyeloablative allogeneic therapy using mat ... Full text Cite

Hematopoietic Cell Transplantation for Sickle Cell Disease: Updated Results of the Multicenter Trial.

Conference Blood · November 16, 2004 AbstractBetween 1991 and 2000, 59 children with symptomatic sickle cell disease (SCD) were enrolled in a multicenter investigation of myeloablative HLA-identical sibling bone marrow transplantation (BMT). Pa ... Full text Cite

Case-based reasoning in care-partner: Gathering evidence for evidence-based medical practice

Conference Lecture Notes in Computer Science Including Subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics · January 1, 1998 This paper presents the CARE-PARTNER system. Functionally, it offers via the WWW knowledge-support assistance to clinicians responsible for the long-term follow-up of stem-cell post-transplant patient care. CAREPARTNER aims at implementing the concept of e ... Full text Cite